12月8日 - ** Structure Therapeutics GPCR.O股价盘前下跌1.4%至34.1美元
** 该药物开发商将于 12 月 8 日 (link) 发布一项研究的数据，该研究评估了其用于治疗肥胖症的每日口服一次的实验性药物 aleniglipron。
** 目前的肥胖症治疗药物包括丹麦制药商诺和诺德公司（Novo Nordisk）的NOVOb.CO Wegovy和礼来公司（Eli Lilly）的LLY.N Zepbound，这两种药物都在市场上占据主导地位。
** 维京治疗公司（Viking Therapeutics）的试验性减肥药VK2735此前在8月份未能 (link)，超出了华尔街的预期。
** 截至上一交易日收盘，GPCR股价年累计上涨27.4%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.